Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8629010 | 0.87 | FAAH (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5810929 | 0.78 | ALDH1A1 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8863095 | 0.78 | POLB (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL278150 | 0.76 | CHRM2 (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9018615 | 0.73 | FAAH (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9018618 | 0.73 | FAAH (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21052112 | 0.73 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8829446 | 0.73 | FAAH (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL888672 | 0.73 | MEN1 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8829438 | 0.70 | MGLL (0.52) | POLBMEN1KMT2AFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093383-A1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE | Cyclacel Limited (GB) | 2001-04-25 | — | — | EP | claimed |
| WO-2000001417-A1 | DELIVERY SYSTEM | CYCLACEL LIMITED (GB) | 2000-01-13 | — | — | WO | claimed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| EP-2087910-B1 | Polymeric prodrugs | ASCENDIS PHARMA GMBH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3922267-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-12-15 | — | — | EP | disclosed |
| EP-2596805-B1 | Prodrug comprising a drug-linker conjugate | ASCENDIS PHARMA AS (DK) | 2021-10-27 | — | — | EP | disclosed |
| US-20210283264-A1 | Polymeric Prodrugs with a Self-Immolative Linker | ASCENDIS PHARMA GMBH (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3085388-B1 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-04-07 | — | — | EP | disclosed |
| EP-3050576-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| EP-1525890-A1 | Protein-Proteophore complexes | Complex Biosystems GmbH (DE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005034909-A2 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | COMPLEX BIOSYSTEMS GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
| EP-1093383-B1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE AND A CYTOTOXIC OR ANTINEOPLASTIC DRUG | CYCLACEL LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004076474-A2 | POLYETHYLENE GLYCOL MODIFIED INTERFERON COMPOSITIONS AND METHODS OF USE THEREOF | INTERMUNE, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CYCLACEL LIMITED OF UNITED KINGDOM | 2003-06-26 | — | — | US | disclosed |
| US-6472507-B1 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | CHRM2 4774/4885CHRM4 4775/4885CHRM5 4834/4885 |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRM2 576/4885CHRM4 1331/4885CHRM5 1318/4885 |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CDYL, CDYL2, DAXX | CHRM2 4369/4885CHRM4 3601/4885CHRM5 3864/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | CHRM2 4774/4885CHRM4 4775/4885CHRM5 4834/4885 |
| US-20210283264-A1 | Polymeric Prodrugs with a Self-Immolative Linker | PAICS, MPI, GPI | CHRM2 2806/4885CHRM4 1994/4885CHRM5 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.